{"id":3677,"date":"2025-01-14T13:43:58","date_gmt":"2025-01-14T13:43:58","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=3677"},"modified":"2025-05-06T07:22:54","modified_gmt":"2025-05-06T07:22:54","slug":"daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","title":{"rendered":"\u7b2c\u4e00\u4e09\u5171\u3001Glycotope\u793e\u304b\u3089\u6297TA-MUC1\u6297\u4f53IP\u3092\u53d6\u5f97"},"content":{"rendered":"<p>\u7b2c\u4e00\u4e09\u5171\u682a\u5f0f\u4f1a\u793e\u306f\u3001\u6297\u816b\u760d\u95a2\u9023\u30e0\u30c1\u30f3-1\uff08TA-MUC1\uff09\u6297\u4f53\u30ac\u30c1\u30dd\u30c4\u30ba\u30de\u30d6\u306e\u77e5\u7684\u8ca1\u7523\u6a29\u3092\u53d6\u5f97\u3059\u308b\u305f\u3081\u3001\u30b0\u30ea\u30b3\u30c8\u30fc\u30d7\u793e\u306b$132.5\u767e\u4e07\u5186\u3092\u652f\u6255\u3046\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u7b2c\u4e00\u4e09\u5171\u306b\u3088\u308b\u3053\u306e\u652f\u6255\u3044\u306f\u30012018\u5e74\u306e\u4e21\u5f53\u4e8b\u8005\u9593\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u5951\u7d04\u306e\u4e00\u74b0\u3068\u3057\u3066\u3001\u30ac\u30c1\u30dd\u30c4\u30ba\u30de\u30d6\u3092\u542b\u3080\u88fd\u54c1\u306e\u30ed\u30a4\u30e4\u30eb\u30c6\u30a3\u3060\u3051\u3067\u306a\u304f\u3001\u6f5c\u5728\u7684\u306a\u81e8\u5e8a\u3001\u85ac\u4e8b\u3001\u8ca9\u58f2\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30f3\u3092\u3059\u3079\u3066\u6e80\u305f\u3059\u3082\u306e\u3067\u3059\u30022018\u5e74\u3001\u7b2c\u4e00\u4e09\u5171\u306f\u30b0\u30ea\u30b3\u30c8\u30fc\u30d7\u793e\u304b\u3089\u6297\u4f53\u85ac\u7269\u8907\u5408\u4f53\uff08ADC\uff09\u3068\u3057\u3066\u30ac\u30c1\u30dd\u30c4\u30ba\u30de\u30d6\u3092\u5168\u4e16\u754c\u3067\u958b\u767a\u30fb\u5546\u696d\u5316\u3059\u308b\u72ec\u5360\u7684\u6a29\u5229\u3092\u30a4\u30f3\u30e9\u30a4\u30bb\u30f3\u30b9\u3002<\/p>\n<p>\u6297TA-MUC1\u306f\u3001\u7b2c\u4e00\u4e09\u5171\u304c\u958b\u767a\u4e2d\u306eADC\u3067\u3042\u308bDS-3939\u306b\u542b\u307e\u308c\u308b\u6297\u4f53\u3067\u3059\u3002DS-3939\u306f\u3001\u7b2c\u4e00\u4e09\u5171\u304c\u958b\u767a\u4e2d\u306eADC\u3067\u3042\u308bDS-3939\u306b\u542b\u307e\u308c\u308b\u6297TA-MUC1\u6297\u4f53\u3067\u3059\u3002 <a href=\"https:\/\/www.daiichisankyo.com\/\">\u7b2c\u4e00\u4e09\u5171<\/a>DS-3939\u306f\u73fe\u5728\u3001\u975e\u5c0f\u7d30\u80de\u80ba\u304c\u3093\u3001\u4e73\u304c\u3093\u3001\u5c3f\u8def\u4e0a\u76ae\u304c\u3093\u3001\u5375\u5de3\u304c\u3093\u3001\u80c6\u9053\u304c\u3093\u3001\u81b5\u81d3\u304c\u3093\u306a\u3069\u306e\u9032\u884c\u56fa\u5f62\u304c\u3093\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2c1\/2\u76f8\u81e8\u5e8a\u8a66\u9a13\u3067\u8a55\u4fa1\u3055\u308c\u3066\u3044\u307e\u3059\u3002DS-3939\u306f\u73fe\u5728\u3001\u975e\u5c0f\u7d30\u80de\u80ba\u304c\u3093\u3001\u4e73\u304c\u3093\u3001\u5c3f\u8def\u4e0a\u76ae\u304c\u3093\u3001\u5375\u5de3\u304c\u3093\u3001\u80c6\u9053\u304c\u3093\u3001\u81b5\u81d3\u304c\u3093\u306a\u3069\u3001\u8907\u6570\u306e\u7a2e\u985e\u306e\u9032\u884c\u56fa\u5f62\u304c\u3093\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2c1\/2\u76f8\u81e8\u5e8a\u8a66\u9a13\u3067\u8a55\u4fa1\u4e2d\u3002<\/p>\n<p>TA-MUC1\u306f\u816b\u760d\u7279\u7570\u7684\u306a\u819c\u8cab\u901a\u578b\u7cd6\u30bf\u30f3\u30d1\u30af\u8cea\u3067\u3001\u3044\u304f\u3064\u304b\u306e\u30b7\u30a2\u30eb\u9178\u8ee2\u79fb\u9175\u7d20\u306e\u767a\u73fe\u30d1\u30bf\u30fc\u30f3\u306e\u5909\u5316\u306b\u3088\u308a\u7cd6\u9396\u4ed8\u52a0\u7570\u5e38\u304c\u898b\u3089\u308c\u307e\u3059\u3002<sup>1<\/sup>\u00a0TA-MUC1\u306f\u307b\u3068\u3093\u3069\u306e\u30d2\u30c8\u4e0a\u76ae\u764c\u3067\u904e\u5270\u767a\u73fe\u3057\u3066\u3044\u308b\u3053\u3068\u304b\u3089\u3001\u764c\u6cbb\u7642\u306e\u9b45\u529b\u7684\u306a\u6a19\u7684\u3067\u3059\u3002<sup>2<\/sup>\u00a0\u73fe\u5728\u3001TA-MUC1\u6307\u5411\u6027\u306e\u6cbb\u7642\u6cd5\u306f\u3001\u3044\u304b\u306a\u308b\u7a2e\u985e\u306e\u764c\u306b\u5bfe\u3057\u3066\u3082\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002<\/p>\n<p>DS-3939\u306f\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30fb\u30a4\u30f3\u30fb\u30af\u30e9\u30b9\u306eTA-MUC1\u6307\u5411\u6027ADC\u3067\u3059\u3002DS-3939\u306f\u3001\u7b2c\u4e00\u4e09\u5171\u72ec\u81ea\u306eDXd ADC\u6280\u8853\u3092\u7528\u3044\u3066\u8a2d\u8a08\u3055\u308c\u3001\u30d2\u30c8\u5316\u6297TA-MUC1\u6297\u4f53\u3068\u30c8\u30dd\u30a4\u30bd\u30e1\u30e9\u30fc\u30bcI\u963b\u5bb3\u5264\uff08\u30a8\u30ad\u30b5\u30c6\u30ab\u30f3\u8a98\u5c0e\u4f53\u3001DXd\uff09\u304c\u30c6\u30c8\u30e9\u30da\u30d7\u30c1\u30c9\u30d9\u30fc\u30b9\u306e\u5207\u65ad\u53ef\u80fd\u306a\u30ea\u30f3\u30ab\u30fc\u3092\u4ecb\u3057\u3066\u7d50\u5408\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><strong>\u30bd\u30fc\u30b9 <a href=\"https:\/\/www.businesswire.com\/news\/home\/20250113621008\/en\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH\">\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\u30fc<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Daiichi Sankyo Company, Ltd\u00a0 announced\u00a0 that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (TA-MUC1) antibody, gatipotuzumab. Such payment by Daiichi Sankyo satisfies all potential clinical, regulatory and sales milestone payments, as well as royalties of products that include gatipotuzumab as part of a 2018 licensing agreement between the parties. In 2018, Daiichi Sankyo in-licensed exclusive rights to develop and commercialize gatipotuzumab worldwide as an antibody drug conjugate (ADC) from Glycotope. The anti-TA-MUC1 is the antibody contained in DS-3939, an ADC being developed by Daiichi Sankyo. DS-3939 is a specifically engineered potential first-in-class TA-MUC1 directed medicine designed using Daiichi Sankyo\u2019s proprietary DXd ADC [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":4141,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[181,89],"tags":[152,151,150,149,105,106],"ppma_author":[205],"class_list":{"0":"post-3677","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-biotech","8":"category-health-tech","9":"tag-antibody","10":"tag-antibody-drug-conjugate","11":"tag-biotech","12":"tag-daiichi-sankyo","13":"tag-itbusinesstoday","14":"tag-news"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP<\/title>\n<meta name=\"description\" content=\"Daiichi Sankyo to pay Glycotope $132.5M for TA-MUC1 antibody gatipotuzumab, fulfilling milestone payments and royalties\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo to pay Glycotope $132.5M for TA-MUC1 antibody gatipotuzumab, fulfilling milestone payments and royalties\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T13:43:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T07:22:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u7b2c\u4e00\u4e09\u5171\u3001\u6297TA-MUC1\u6297\u4f53IP\u3092\u53d6\u5f97","description":"\u7b2c\u4e00\u4e09\u5171\u3001TA-MUC1\u6297\u4f53gatipotuzumab\u306b\u3064\u3044\u3066Glycotope\u793e\u306b$1\u51043,250\u4e07\u30c9\u30eb\u3092\u652f\u6255\u3044\u3001\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3068\u30ed\u30a4\u30e4\u30ea\u30c6\u30a3\u3092\u5c65\u884c","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","og_locale":"ja_JP","og_type":"article","og_title":"Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP","og_description":"Daiichi Sankyo to pay Glycotope $132.5M for TA-MUC1 antibody gatipotuzumab, fulfilling milestone payments and royalties","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","og_site_name":"itbusinesstoday","article_published_time":"2025-01-14T13:43:58+00:00","article_modified_time":"2025-05-06T07:22:54+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP from Glycotope","datePublished":"2025-01-14T13:43:58+00:00","dateModified":"2025-05-06T07:22:54+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/"},"wordCount":244,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","keywords":["antibody","antibody drug conjugate","Biotech","Daiichi Sankyo","itbusinesstoday","News"],"articleSection":["Biotech","Health Tech"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/","name":"\u7b2c\u4e00\u4e09\u5171\u3001\u6297TA-MUC1\u6297\u4f53IP\u3092\u53d6\u5f97","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","datePublished":"2025-01-14T13:43:58+00:00","dateModified":"2025-05-06T07:22:54+00:00","description":"\u7b2c\u4e00\u4e09\u5171\u3001TA-MUC1\u6297\u4f53gatipotuzumab\u306b\u3064\u3044\u3066Glycotope\u793e\u306b$1\u51043,250\u4e07\u30c9\u30eb\u3092\u652f\u6255\u3044\u3001\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3068\u30ed\u30a4\u30e4\u30ea\u30c6\u30a3\u3092\u5c65\u884c","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Daiichi-Sankyo-Acquires-Intellectual-Property-Rights-for-Anti-TA-MUC1-Antibody-in-DS-3939-from-Glycotope-GmbH-1.webp","width":1200,"height":800,"caption":"Daiichi Sankyo"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/daiichi-sankyo-acquires-anti-ta-muc1-antibody-ip-from-glycotope\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP from Glycotope"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/3677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=3677"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/3677\/revisions"}],"predecessor-version":[{"id":3687,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/3677\/revisions\/3687"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/4141"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=3677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=3677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=3677"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=3677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}